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Abstract
Background: A substantial increase in pulmonary and extra-pulmonary diseases due to non-tuberculous
mycobacteria (NTM) has been documented worldwide, especially among subjects suffering from chronic respiratory
diseases and immunocompromised patients. Many questions remain regarding the epidemiology of pulmonary
disease due to NTM (NTM-PD) mainly because reporting of NTM-PD to health authorities is not mandated in several
countries, including Italy. This manuscript describes the protocol of the first Italian registry of adult patients with
respiratory infections caused by NTM (IRENE).
Methods: IRENE is an observational, multicenter, prospective, cohort study enrolling consecutive adult patients with
either a NTM respiratory isolate or those with NTM-PD. A total of 41 centers, including mainly pulmonary and
infectious disease departments, joined the registry so far. Adult patients with all of the following are included in the
registry: 1) at least one positive culture for any NTM species from any respiratory sample; 2) at least one positive
culture for NTM isolated in the year prior the enrolment and/or prescribed NTM treatment in the year prior the
enrolment; 3) given consent to inclusion in the study. No exclusion criteria are applied to the study. Patients are
managed according to standard operating procedures implemented in each IRENE clinical center. An online case
report form has been developed to collect patients’ demographics, comorbidities, microbiological, laboratory,
functional, radiological, clinical, treatment and outcome data at baseline and on an annual basis. An IRENE biobank
has also been developed within the network and linked to the clinical data of the registry.
Conclusions: IRENE has been developed to inform the clinical and scientific community on the current
management of adult patients with NTM respiratory infections in Italy and acts as a national network to increase
the disease’s awareness.
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Background
Pulmonary disease due to non-tuberculous mycobacteria
(NTM) has always been a tangible clinical entity [1]. An in-
crease in NTM pulmonary and extra-pulmonary morbidity
and mortality has been documented in Italy and worldwide,
especially among patients suffering from chronic respira-
tory diseases, including bronchiectasis, chronic obstructive
pulmonary disease (COPD), or cystic fibrosis (CF), as well
as among HIV-positive and other immunocompromised
patients [2–11]. Several determinants of the increasing epi-
demiological trend have been identified: the aging of the
population with high prevalence of chronic and debilitating
diseases; an intensified use of immunosuppressive therapies;
a broader use of chest CT; a high diagnostic yield of micro-
biological conventional and molecular techniques; an in-
creasing environmental exposure to NTM; an increase use
of antibiotics which can favor the occurrence of niches for
NTM; declining rates of M. tuberculosis infection; and a
potential impact of person-to-person transmission as re-
cently suggested among CF patients [12, 13].
Many questions remain regarding the epidemiology of
pulmonary disease due to NTM (NTM-PD), which is char-
acterized by symptomatic, progressive inflammatory lung
damage and defined in 2007 in the American Thoracic So-
ciety (ATS) / Infectious Diseases Society of America (IDSA)
guidelines [14, 15]. These epidemiological and clinical un-
certainties on NTM-PD cause significant confusion for cli-
nicians in daily clinical practice when asked to diagnose
NTM-PD. The clinical relevance of specific NTM respira-
tory isolates significantly varies from patient to patient, and
the interplay between exposure- and host-related factors is
poorly understood [15]. NTM-PD shows a wide spectrum
of clinical manifestations and frequently is diagnosed in the
context of concomitant respiratory diseases (e.g., bronchiec-
tasis, COPD, or CF) [3]. Geographical diversity is another
important factor in the epidemiology of NTM. A large in-
ter- and intra-country heterogeneity in distribution of
NTM species has been recently shown [16, 17]. Finally, an
Italian experience described NTM-PD risk factors whose
qualitative and quantitative ascertainment could help clini-
cians to discriminate between colonization and disease [18].
Reporting of NTM-PD to health authorities is not
mandated in several countries and the current estimates
have been obtained from sentinel surveillance or
laboratory-based studies, retrospective cohort studies, or au-
dits of administrative databases. Only few European coun-
tries (i.e., UK, Greece, Germany, and the Netherlands) have
provided epidemiological data, showing an incidence rate of
NTM isolation ranging from 2.9 to 7.0 per 100,000 popula-
tion and a NTM-PD prevalence of 0.7–1.7 per 100,000
population, with a marked increase as aging occurs [19–21].
Until now no data have been published on the epidemiology
of respiratory NTM infections in Italy.
On this basis, robust national longitudinal data are
needed. This manuscript describes the protocol of the
first Italian registry of adult patients with respiratory in-
fections caused by NTM.
Methodology of the Irene registry
Study design
The Italian registry of pulmonary NTM (IRENE) is an ob-
servational, multicenter, prospective, cohort study enrolling
consecutive adult patients with either a NTM respiratory
isolate or those with NTM-PD. The coordinating center is
located at the Pulmonary Department of the Fondazione
IRCCS Ca′ Granda, Ospedale Maggiore Policlinico (hereby
referred to as Policlinico Hospital), Milan, Italy, where the
central approval from the Ethical Committee (EC) for this
study was obtained on March 6th, 2017, and the first pa-
tient was enrolled on April 21st, 2017. A total of 42 centers,
including mainly pulmonary and infectious disease (ID) de-
partments, joined the registry so far, see Fig. 1. All the cen-
ters are also required to obtain local EC approval before
entering the registry. All patients must provide written in-
formed consent to participate in the registry. The study is
sponsored by the Policlinico Hospital in Milan. The study
website is located at www.registroirene.it and the study has
been registered at clinicaltrial.gov (NCT03339063).
Study subjects
Adult (≥18 years) patients with all of the following are in-
cluded in the registry: 1) at least one positive culture for
any NTM species from any respiratory sample; 2) at least
one positive culture for NTM isolated in the year prior the
enrolment and/or prescribed NTM treatment in the year
prior the enrolment; 3) given consent to inclusion in the
study. No exclusion criteria are applied to the study in
order to increase the generalizability of the results. The in-
clusion criteria of the registry clearly identify a population
of patients characterized by a recent/ongoing history of ei-
ther a NTM infection or NTM-PD (Table 1). Patients who
received NTM treatment in the year prior to enrolment
but did not have a positive culture for NTM isolated in this
period of time could be included in the study if still they
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had at least one positive culture for any NTM species from
any respiratory sample in their history. The IRENE Execu-
tive Committee decided not to limit the enrolment to pa-
tients with NTM-PD, but to follow up also patients with a
recent NTM infection not fulfilling the 2007 ATS/IDSA
criteria for NTM-PD [15].
Patients included in the registry are mainly recruited
among pulmonary and ID out- and in-patient services.
Adult CF, lung transplant, and tuberculosis clinics represent
other recruitment centers. A heterogeneous population of
patients with NTM infection/NTM-PD sharing different
clinical phenotypes is expected to be enrolled in the regis-
try. IRENE has a special focus on four patients’ categories:
1) immunocompetent/bronchiectatic, 2) HIV-positive, 3)
CF and 4) lung transplanted patients. 500 patients are ex-
pected to be enrolled in the registry by the end of 2020.
The registry has been developed to accept an unlimited
number of patients and no deadlines have been decided.
Data collection, definitions and quality control
Patients are managed according to standard operating pro-
cedures (SOPs) implemented in each IRENE clinical center
without any interference from the study team. A baseline
case report form (CRF) is collected at patient’s enrolment
including demographics, comorbidities, microbiological, la-
boratory, functional, radiological, clinical, and treatment
data. Then, study investigators will enter follow-up data on
an annual basis. Furthermore, a “start treatment” and a
“stop treatment” CRFs are also collected. The database in-
corporates automated logic checks put in place to avoid the
collection of out-of-range values. Once the case is entered
into the registry, two members of the study team (SA and
MS) manually verified its consistency and data queries will
be solved with the local study investigator. In case of unre-
solved queries or incomplete cases, they will be rejected to
have high quality data. To assure the high quality of the
data, random audit will also be conducted at study sites.
IRENE biobank
An IRENE biobank has also been developed within the
network and linked to the clinical data of the registry.
IRENE sites can collect samples, including blood, serum,
plasma, respiratory specimens (e.g., sputum, induced
Fig. 1 The IRENE study site
Table 1 IRENE inclusion and exclusion criteria
Inclusion criteria (all of them)
• Adults (≥18 years)
• Any ethnicity
• Any gender
• At least one positive culture for any non-tuberculous mycobacteria
species from any respiratory sample
• At least one positive culture for non-tuberculous mycobacteria iso-
lated in the year prior the enrolment and/or prescribed treatment for
non-tuberculous mycobacteria in the year prior the enrolment
• Given consent to inclusion in the study
Exclusion criteria
• None
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sputum, tracheal aspirate, or bronchoalveolar lavage),
urine, and NTM isolates at the first visit and during
follow-up on a voluntary basis. The same SOPs for bio-
logical collection, processing, and storage (first locally
and then centralized at the Policlinico Hospital in Milan
for analysis) will be adopted by all IRENE sites.
The registry governance and the IRENE network
The registry is held securely at the Health Informatics
Centre (HIC) of the Policlinico Hospital in Milan, Italy,
and de-identified data will be accessible to the principal
investigator and to all IRENE investigators on request to
the Executive Committee. Analysis of the entire IRENE
database will be allowed after the submission of a research
question, along with a specific study protocol, to the
IRENE Scientific Committee. IRENE investigators will
have unrestricted access to their own data. The database
will be run in accordance with the principles of Good
Clinical Practice. Study results will be disseminated in the
form of annual reports, conference abstracts, and peer
reviewed publications. The IRENE network will follow the
International Committee of Medical Journal Editors rec-
ommendations regarding authorship.
IRENE is the official Italian network within the EMBARC
European NTM registry [22]. The EMBARC (European
Multicentre Bronchiectasis Audit and Research Collabor-
ation) registry is a prospective, pan-European observational
study of adult patients with bronchiectasis, including those
with NTM. Patients enrolled in the EMBARC registry
undergo a comprehensive baseline assessment and are
followed-up annually for up to 5 years with the goal of pro-
viding high-quality longitudinal data on outcomes, treat-
ment patterns and quality of life [22]. All Italian patients
included in the EMBARC European NTM registry will be
enrolled through IRENE and IRENE data will be incorpo-
rated into the EMBARC European NTM registry.
IRENE also promotes multi-disciplinary education and
patient-professional collaboration in the field of NTM
through its relationship with national scientific societies.
There is a lack of a platform for communication be-
tween patients with NTM infection/NTM-PD and physi-
cians in Italy and some patients within the IRENE
network already expressed their will to develop a patient
advisory group.
The NTM Consilium
Inspired by recent successful initiatives supporting phy-
sicians in their decisions to manage difficult-to-treat pa-
tients with respiratory infection, such as the ERS/WHO
TB Consilium, a free-cost, Italian, interned-based con-
sultation system will be developed within the IRENE
website, the IRENE NTM Consilium [23]. IRENE inves-
tigators will have access to this platform to seek advice
from national experts on the clinical management of
complicated NTM cases and will receive a suggestion in
less than 3 working days. A call for experts will precede
the launch of this initiative.
Discussion
Several registries and merging platforms for international
cohorts have been developed on different respiratory dis-
eases, including community-acquired pneumonia (the
CAPO database), bronchiectasis (EMBARC and FRIENDS),
or primary ciliary dyskinesia over the past decades [24, 25].
Registries are invaluable tools which can help investigators
to better understand the natural history, the epidemiology,
and the management of a specific disease [26]. Results from
the registries may inform both the clinical community on
real-life data and the scientific experts on tracks for future
interventional studies.
The largest registry including NTM patients running so
far is the United States Bronchiectasis Research Registry
(BRR) which is a database sponsored by the COPD Founda-
tion and which has enrolled 1826 non-CF bronchiectasis
patients at 13 sites in the USA until now [27]. The first re-
port from the BRR has been recently published showing 63
% of the population with a history of NTM disease or
NTM isolation [27]. Important differences between bron-
chiectasis patients with and without NTM were identified
by the authors. Although extremely informative, this regis-
try has been mainly developed as a bronchiectasis registry
with some specific data on NTM-PD. IRENE may integrate
BRR data because it includes > 40 sites where NTM pa-
tients are cared by both pulmonary and ID physicians to
fully explore the disease heterogeneity.
IRENE has been developed: 1) to strengthen the network
of pulmonologists, infectious diseases physicians, and other
healthcare providers caring for adult patients with NTM; 2)
to prospectively collect demographics, clinical, microbio-
logical, radiological, functional, and therapy variables, as
well as long-term outcomes; 3) to longitudinally collect
clinical, biological and mycobacteriological samples for fu-
ture translational research on NTM; 4) to assess the hetero-
geneity in the clinical manifestation of the disease and its
current management; 5) to release national SOPs and
guidelines based on precise epidemiological data; 4) to in-
crease NTM disease awareness at national and inter-
national levels. The IRENE network is composed by
pulmonologists, ID physicians, clinical microbiologists, tu-
berculosis, CF and lung transplant specialists, radiologists,
public health experts, translational researchers, an inter-
national advisory board of NTM experts, as well as patients
suffering from NTM infections. IRENE has been designed
to be open for collaboration with other national and inter-
national registries in the field of NTM. The IRENE data
fields and protocol are aligned with the European NTM
registry to ensure data can be shared between IRENE and
the European NTM Registry for collaborative analysis [22].
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Conclusions
NTM-PD is considered a neglected and rare disease and
there are limited observational and experimental data on
epidemiology of this condition and its management. A
substantial improvement in the understanding of NTM
infection and NTM-PD is needed to develop new ther-
apies and improve patients’ outcomes. IRENE has been
developed to inform the clinical and scientific commu-
nity on the current management of adult patients with
NTM respiratory infections in Italy and acts as a na-
tional network to increase the disease’s awareness.
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